

Technology Advisory Committee B Interests Register
Topic [ID1213] Dupilumab for treating severe asthma
Publication Date: 8 December 2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Peter Wheatley-Price	Committee Member	Personal specific financial	Mr Peter Wheatley-Price owns shares in GlaxoSmithKline, one of the comparator manufacturers.		11/02/2020		It was agreed that Mr Wheatley-Price would not participate in this appraisal.
Professor Ian Pavord	Clinical Expert	Personal financial	He has received honoraria for speaking at meetings from AstraZeneca, Novartis, Teva, Sanofi/Regeneron and GSK; payments for organising educational events from AstraZeneca, GSK, Sanofi/Regeneron and Teva; honoraria for attending advisory panels with Sanofi/Regeneron, AstraZeneca, BGSK, Novartis, Teva; payments to support FDA approval meetings from GSK; sponsorship to attend international scientific meetings from GSK, AstraZeneca and Teva.		11/02/2020		It was agreed that this declaration would not prevent Professor Pavord from participating in this section of the meeting.

Dr James Fotheringham	Committee Member	Financial Interest	Dr James Fotheringham received speaker honoraria and consultancy fees from Novartis for health economic modelling and risk prediction in solid organ transplantation.		09/09/2021		It was agreed that his declaration would not prevent Dr James Fotheringham from participating in this section of the meeting.
Dr Nick Latimer	Committee Member	Non-Financial Professional & Personal Interests	Dr Nick Latimer is a the member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company.		09/09/2021		It was agreed that his declaration would not prevent Dr Nick Latimer from participating in this section of the meeting.